Jun 19, 2019
Global Hereditary Angioedema (HAE) Markets, 2017-2018 & 2019-2026
Jun 08, 2018
Global Hereditary Angioedema Market Forecast 2018-2028 - Visiongain Report
May 30, 2018
Asia-Pacific Hereditary Angioedema (HAE) Therapeutics Markets 2016-2018 & 2023
Mar 15, 2018
CSL Behring Receives Patient Impact Award For Subcutaneous Prophylactic Treatment To Prevent Hereditary Angioedema Attacks
Nov 20, 2017
Plasma Protease C1-inhibitor Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025
Oct 29, 2017
Data on the Preventive Effects of HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) in Subjects with Very Frequent HAE Attacks Presented by CSL Behring at the 2017 ACAAI Annual Scientific Meeting
Oct 24, 2017
New Data for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) to be presented at the 2017 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
Oct 24, 2017
Plasma Protease C1-inhibitor Treatment Market Worth US$7.9 Billion by 2025, Globally: Transparency Market Research
Aug 23, 2017
Hereditary Angioedema Market to be Worth US$3.81 Billion by 2025: Initiatives to Generate Awareness by Physicians and Patient Bodies Drive Growth
Jul 25, 2017
HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) Now Available in the United States for Patients with Hereditary Angioedema
Jul 21, 2017
CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human])
Jun 23, 2017
FDA Approves HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), First and Only Subcutaneous Preventive Treatment for Hereditary Angioedema